December 2018
-
Media ReleaseSandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use DisorderreSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-…
-
Media ReleaseSandoz certified Top Employer Asia Pacific 2019Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute…
November 2018
-
Media ReleaseSandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications1 Ziextenzo is indicated to…
-
Media ReleaseSandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use DisorderreSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
-
Media ReleaseSandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR)Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health1 Sandoz, as the world’s leading provider of high-quality antibiotics, is…
-
Media ReleaseSandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needsDecision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
October 2018
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)Biosimilar Hyrimoz™ (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity Biosimilars are critical to sustaining US healthcare system, providing…
-
Media ReleaseNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growthNet sales grew 6% (cc1, +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113% cc)…
-
Media ReleaseSandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient accessGlobal resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®** Resolution paves way for 2018 launch in key European markets and secures…
-
Media ReleaseSandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challengesDespite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year’s competition expands to seek…
September 2018
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastimPositive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality Sandoz seeks approval in the…
-
Media ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to AurobindoNovartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic oral…